论文部分内容阅读
本文应用6种胃癌单克隆抗体混合物,以酶联结合抑制法分别测定了47例胃癌、28例慢性浅表性胃炎,15例慢性萎缩性胃炎,27例消化性溃疡,14例食管癌者患者胃液中上述单抗的相应抗原MG-Ags的含量。以抑制率≥60％计算各组阳性率,分别为78.7％、14.3％、33.0％、14.8％、和7.1％。并在胃癌组中观察到,随着癌灶增大,MG-Ags含量增加。酶联结合抑制法操作简便,重复性、敏感性、特异性较好。用此法测定胃液中肿瘤相应抗原的MGs含量,有助于临床诊断,有助于判定病情进展,治疗效果和预后,也有助于在高危人群中检出胃癌。
In this paper, six gastric cancer monoclonal antibody mixtures were used to determine 47 cases of gastric cancer, 28 cases of chronic superficial gastritis, 15 cases of chronic atrophic gastritis, 27 cases of peptic ulcer, and 14 cases of esophageal cancer by enzyme linked inhibition assay. The content of MG-Ags, the corresponding antigen of the above monoclonal antibody in gastric juice. The positive rate of each group was calculated with the inhibition rate ≥ 60%, which were 78.7%, 14.3%, 33.0%, 14.8%, and 7.1%, respectively. And in the gastric cancer group, the MG-Ags content increased with the increase of cancer foci. Enzyme-linked binding inhibition method is simple, reproducible, sensitive and specific. The use of this method to determine the MGs content of tumor antigens in gastric juice is helpful for clinical diagnosis, help to determine the disease progression, treatment effect and prognosis, and also helps to detect gastric cancer in high-risk populations.